- Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial Barron’s
- For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat statnews.com
- Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Intellia Therapeutics
- Intellia Pauses Crispr Trials After Patient Is Hospitalized Bloomberg.com
- Intellia pauses phase 3 CRISPR trials after patient is hospitalized Fierce Biotech
Source link
